Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC
Conditions
Interventions
Budigalimab
Livmoniplimab
+2 more
Locations
59
United States
Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313
Prescott Valley, Arizona, United States
Highlands Oncology Group, PA /ID# 253158
Springdale, Arkansas, United States
University of California, Los Angeles /ID# 253292
Los Angeles, California, United States
UC Irvine /ID# 252707
Orange, California, United States
California Pacific Medical Center - San Francisco - Webster Street /ID# 253291
San Francisco, California, United States
Rocky Mountain Cancer Centers - Denver Midtwon /ID# 254163
Denver, Colorado, United States
Start Date
September 21, 2023
Primary Completion Date
November 1, 2026
Completion Date
November 1, 2026
Last Updated
August 14, 2025
NCT07175441
NCT05969860
NCT06427941
NCT07164313
NCT07118202
NCT06503146
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions